Smite is a mechanic in Soulframe that allows you to do additional damage to enemies. Many weapons will have a Smite stat, usually reading something like "3 in 50" as shown above. This means you have a ...

Quin Callahan is a professional writer with over eight years of experience creating gaming content. In addition to games writing, he's also produced TTRPG content for a variety of tabletop publishers.

A gamer, Dungeon Master, and novelist before all else, Shane writes for DualShockers to immerse himself even more in the gloriousness of nerd culture. If he's not analyzing the narrative of a game or ...

A gamer, Dungeon Master, and novelist before all else, Shane writes for DualShockers to immerse himself even more in the gloriousness of nerd culture. If he's not analyzing the narrative of a game or ...

Layoffs are happening at Hi-Rez Studios as the group moves to reform its priorities around Smite 2. Alongside an layoff of allegedly 70 employees, several games in the Hi-Rez portfolio are halting ...

Smite and Realm Royale developer and publisher Hi-Rez is shifting most of its remaining staff and resources away from some of its current games in order to support 2024’s Smite 2. This means the ...

Jo Craig (they/them) is a writer on Game Rant from Scotland and has been in the industry for nearly a decade dissecting comic book movie trailers for hours and diving headfirst into horror. They still ...

SMITE 2 has technically been out and available to play on PS5 since last August, but it was also, technically, still in an alpha state. It’ll be entering its open beta phase next week on January 14, ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Titan Forge Games has announced that Smite 2 will be going free-to-play later this month. The wait ...

Hi-Rez Studios has finally confirmed a release date for the free-to-play open beta version of Smite 2. That free-to-play launch is coming next Tuesday, January 14. Currently, Smite 2 features 45 ...

Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single patient was enrolled. The withdrawal, which ApexOnco reported earlier this ...